The review by Bushe et al. 1 in this issue of the Annals draws attention to the detection and investigation of hyperprolactinaemia in patients treated with antipsychotic drugs. An editorial 2 in the British Medical Journal in 2002 indicated that it had been known for 25 y that antipsychotic drugs could cause symptomatic hyperprolactinaemia, but this had attracted little clinical and scientific interest. Clinical recommendations have now been published 3 and raise a number of issues for clinical biochemists.
Workload
The recommendations 3 are to measure serum prolactin in the following circumstances: † All patients before commencing treatment with antipsychotic drugs, regardless of the drug to be used; † All patients after three months of treatment with an unchanged dose; † When relevant clinical symptoms develop.
If serum prolactin concentration is within the reference interval, further measurements are not recommended unless relevant symptoms develop or the antipsychotic medication or dose is changed.
If serum prolactin is found to be elevated on treatment, further recommendations are linked to the observed prolactin concentration as follows: † Prolactin ,1000 mU/L: The serum prolactin concentration should be monitored and should not be allowed to remain elevated long term; † Prolactin .1000 mU/L should prompt consideration of change in antipsychotic medication or dose; † Prolactin .3000 mU/L should prompt referral to an endocrinologist and investigation for prolactinoma.
Given these recommendations and given the fact that antipsychotics are often utilized outside their licensed applications, 1 the potential workload for the laboratory from patients treated with antipsychotic drugs is considerable. This is illustrated in a recent report that indicated that 25% of prolactin requests came from psychiatry. 4
Reference intervals
The upper limit of the reference interval for serum prolactin is clearly an important factor in the recommendations 3 since this will determine which patients have hyperprolactinaemia. In their review, Bushe et al. 1 comment that 'hyperprolactinaemia is often regarded by psychiatrists as a prolactin concentration greater than the upper reference limit of the local laboratory, which may depend on the type of assay used'. The variation in reference intervals for serum prolactin and the differences in results given by different assays have been issues for clinical biochemists for many years. Now is an appropriate time to reconsider them, given the recommendations on measuring prolactin in patients undergoing treatment with antipsychotics. 3 United Kingdom National External Quality Assessment Scheme (UK NEQAS) surveys using human serum containing only endogenous prolactin show substantial differences, typically of up to 30%, in the results given by different assays despite most of them being calibrated against the same International Standard material (IS 84/500) ( Figure 1a ). A different pattern of assay bias is seen with serum spiked with IS or with recombinant forms of prolactin, and these results suggest that the different results may reflect differences in the reactivity of the different antibodies used in the prolactin assays for different isoforms of prolactin. Assay bias is poorly related to recovery of added standard IS 84/500, providing further evidence for the importance of assay configuration and choice of antibody as being important factors in the cause of assay bias ( Figure 1b ).
Reference intervals provided by manufacturers vary considerably (Table 1 ) and differences are not simply related to assay bias. Thus, the lowest upper limit of the female reference interval is quoted for the Ortho Vitros assay (395 mU/L) and the highest for the Abbott Architect (629 mU/L) while both assays have a positive assay bias (Figure 1a ). While manufactures are careful to indicate that reference intervals given in kit inserts are for guidance only and should be confirmed by each laboratory, the reference intervals quoted are often poorly defined. They may be based on few cases and may have been derived in an earlier method, with validation being by comparison between the previous and current method. A recent study 5 which determined reference intervals for five widely used assays for prolactin using the same reference panel showed good agreement with the intervals quoted by only one manufacturer (Roche Elecsys II assay, Roche Diagnostics Ltd., Burgess Hill, UK); for other assays, the upper limit of the reference interval for serum prolactin in women was between 78% (Centaur, Siemens Healthcare Diagnostics, Camberley, UK) and 34% (Immulite, Siemens Healthcare Diagnostics, Camberley, UK) lower.
UK NEQAS surveys show considerable differences in the reference intervals quoted by laboratories. A recent survey undertaken in February 2007 6 indicated that:
(1) The majority of laboratories relied on reference intervals provided by their assay manufacturer, sometimes not using the current manufacturer data; (2) There was no relationship between kit insert reference intervals and method bias, as observed in the UK NEQAS specimens; (3) Only 17% established reference intervals in-house, and these often differed considerably from those in the kit insert;
(4) Many laboratories (20%) used the same reference interval for men and women, despite well-recognized sex-dependent differences; (5) Some laboratories (53%) considered that any prolactin concentration above the upper limit of the reference interval required further investigation. The remainder (47%) regarded mild elevation of prolactin above the upper limit of normal as unlikely to be of clinical significance and set a higher value for the prolactin concentration that required further action. However, most of these laboratories appeared to have been influenced by the recommendations of Jeffcoate et al. 7 which were concerned with the almost exclusive application of the assay at that time in the detection of prolactinoma in women. Based on extensive clinical experience, it was proposed that serum prolactin ,700 mU/L be considered normal and this value was frequently quoted by UK laboratories as their action limit.
In conclusion, there is good evidence that reference intervals for serum prolactin are often inaccurate and inappropriate for patients undergoing treatment with antipsychotics and we suggest the following actions:
(1) Manufacturers should review their reference intervals for serum prolactin and consider carrying out further studies in line with recommended practice 8 to improve their accuracy; (2) Laboratories should review their quoted reference intervals and consider whether these are appropriate for patients undergoing treatment with antipsychotics; (3) It seems probable that inaccurate reference intervals for serum prolactin will have affected the data reviewed by Bushe et al. 1 and the estimates of the prevalence of hyperprolactinaemia in patients treated with antipsychotics and estimates of the prevalence by antipsychotic. 
Screening for macroprolactinaemia
Hyperprolactinaemia due to macroprolactin leading to misdiagnosis and inappropriate investigation of patients for prolactinoma is well described. 10 Screening for macroprolactinaemia is widely acknowledged as best laboratory practice and is common in laboratories in the UK and Ireland. Since macroprolactinaemia is a chance phenomenon, this interference will also be encountered with similar frequency in patients with serious mental illness and could similarly lead to diagnostic confusion. We suggest that screening for macroprolactinaemia should be extended to the pretreatment samples in this group of patients and that a measure of monomeric prolactin be reported when macroprolactinaemia is detected. In subjects with macroprolactinaemia, any stimulus to pituitary secretion of monomeric prolactin will lead to a slower but commensurate increase in the macroprolactin component. 11 In such cases a measure of the bioactive, monomeric prolactin concentration will be more meaningful. 5 
